Skip over navigation

Rare Cancers Europe logo

  • About Rare Cancers
    • Definition of Rare Cancers
    • "Families" and List of Rare Cancers
    • The Burden and the Challenges of Rare Cancers
    • The Added Value of Research on Rare Cancers
  • About the Campaign - Objectives
  • Call to Action
    • Full text
    • Signatories
  • Political Recommendations
  • EU initiatives
  • How to get involved
  • News
    • 24 May 2013: International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
    • 21 November 2012: Joint Statement on EU Clinical Trials Regulation
    • 3 October 2012: Survey Open: Access to Rare Cancer Care in the EU – Have Your Say!
    • 20 July 2012: International survey on Pathology in Rare Cancers launched
    • 12 June 2012: U.S. NCI issues guidance for deliberations on rare cancer trial closures
    • 4 June 2012: Rare cancer research project announces world’s largest release of human cancer genome data
    • 2 April 2012: Cancer Cell Line Encyclopedia may help to improve rare cancer research
    • 27 March 2012: European Alliance for Personalised Medicine calls for early access to personalised medicine
    • 12 March 2012: ESMO Conference on Sarcoma and GIST: Doctors lack awareness of rare forgotten cancers
    • 21 February 2012: European conference explores ways to improve clinical research on rare cancers
    • 15 February 2012: International Childhood Cancer Day: Calls for policy changes
    • 24 November 2011: International Rare Cancers Initiative: EORTC – UK – US Global Collaboration
    • 16 November 2011: Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases adopted by EUCERD
    • 10 November 2011: EU consultation to improve recognition of cross-border prescriptions
    • 24 September 2011: Rare Cancers Europe: New name and new action
    • 24 September 2011: European Multidisciplinary Cancer Congress highlights challenges posed by rare cancers
    • 12 July 2011: EP Workshop on Rare Cancers: The Added Value of Closer Cooperation
    • 20 May 2011: European Platform for Rare Disease Registries
    • 31 March 2011: EurocanPlatform for cross border cancer research launched
    • 22 March 2011: EU Register of Clinical Trials launched Online
    • 15 March 2011: European childhood cancer research in danger
    • 28 February 2011: Rare Disease Day – Focus on Health Inequalities
    • 15 February 2011: MEPs remember Children with Cancer
    • 12 January 2011: EP Meeting: Challenges of Rare Cancers
    • 27 November 2010: Open Letter concerning 2011 UN Summit on Non-Communicable Diseases
    • 9 October 2010: ESMO Rare Cancers Press Briefing
    • 9 October 2010: ESMO 2010 Rare Cancers Press Briefing Videos
    • 7 October 2010: Underestimated Obstacles to Rare Cancer Care
    • 5 October 2010: EP Meeting: Orphan Drugs for Rare Cancers
    • 13 September 2010: European Action Against Rare Cancers Secretariat
    • 9 December 2009: EU Committee of Experts on Rare Diseases
    • 24 June 2009: Launch of European Action Against Rare Cancers
    • 10 December 2008: Rare cancers are common; optimal care is not
  • Rare Cancers Conference 2012
  • Surveys
  • Events
  • Cooperating organisations
    • Campaign Organisation Committee
    • Governance principles
    • Video testimonials from Cooperating organisations
    • Quotes from the Cooperating organisations
  • Corporate supporters
  • Links
    • General Cancer Patient Support Organisations and Sites
    • Rare Cancer Type-Specific Patient Support Organisations and Sites
    • General Professional Organisations, Research Organisations and Sites
    • Cancer Type-Specific Professional Organisations, Research Initiatives and Sites
    • Clinical Practice Guidelines for Professionals and Guides for Patients
  • Campaign materials
  • Contact us

27 November 2010: Open Letter concerning 2011 UN Summit on Non-Communicable Diseases

An open letter to all those associated with the September 2011 UN Summit (High Level Meeting) on Non-Communicable Diseases

The UN Summit on Non-Communicable Diseases (NCDs) in September 2011 will be an important meeting and has the potential to compare in significance to the 2001 high level UN Summit on HIV/AIDS, which marked a crucial turning point in the treatment of that disease.

As happened in 2001 there is an emerging tension in 2010 between those who believe that such a meeting should concentrate on prevention, and those who believe that support and research into a cure for NCDs are also crucial. This is particularly so in regard to cancer, which is a major NCD affecting people in all areas of the world.

Already, one significant European leader has argued that prevention is cheaper than disease management and that it makes sense to prioritise and pursue such policies, particularly because of the pressures on government expenditure. A number of the signatories to this open letter are involved with the support of patients who have a so-called rare cancer, or a less common, or intransigent, cancer. These diseases have utterly dire prognoses; cause enormous stress to patients, families and caregivers; and, when taken together, amount to a large group of cancers which suffer from an unacceptable level of unmet medical need in many parts of the globe, especially in developing regions.

Very often the causes of these cancers are unknown, hence prevention is impossible. Therefore, for rare and less common cancers, the focus should be on increased research and support.

We therefore believe that it should be a major aim of the cancer input to the UN Summit on NCDs to ensure that the voices of those with unpreventable cancers are not ignored.

This is particularly so with regard to all paediatric cancers which, because of low incidence rates, are by definition categorised as rare. However, rarity does not reduce the devastating impact such a diagnosis has on both the individuals concerned and on the wider society in general.

The President of the United States said in September 2010: “…Cancer is still the leading cause of death by disease for young Americans between infancy and age 15.” He added: “Tragically, the causes of cancer in children are largely unknown” and indicated his support for a greater research effort.

While recognizing that for a few cancers prevention strategies are very relevant and admirable, we call on those associated with the 2011 UN Summit to ensure that – for people with rare and less common cancers – a greater effort is made for enhancing support and significantly increasing research.

The undersigned therefore request that rare and less common cancers are formally acknowledged in the proceedings of the UN Summit on Non-Communicable Diseases (NCDs) as requiring a greater focus of attention by the worldwide cancer community.

Signed by the cooperating organisations of the European Action Against Rare Cancers (EAARC):
- European Society for Medical Oncology (ESMO)
- European Organisation for Rare Diseases (Eurordis)
- European Cancer Patient Coalition (ECPC)
- European Organisation for Research and Treatment of Cancer (EORTC)
- Conticanet
- EuroBoNeT
- Association of European Cancer Leagues (ECL)
- Chronic Myeloid Leukaemia Support Group
- International Brain Tumour Alliance (IBTA)
- Orphanet
- Chronic Myeloid Leukaemia Advocates Network
- Fondazione IRCCS Istituto Nazionale dei Tumori
- European Institute of Oncology (IEO)
- European Society of Pathology (ESP)
- Novartis Oncology

200. Call to Action

© Rare Cancers Europe 2012. All rights reserved.
We welcome requests for permission to reprint or translate the information on this website, including the Call to Action Against Rare Cancers, for non-commercial use. However, the content, layout and logo of the website may not be copied without attribution to the campaign, and no modifications of the content, layout or logo are permitted. The cooperating organisations behind this campaign have made every effort to provide accurate information on this website. However, the cooperating organisations and corporate supporters accept no liability for any inaccuracies or omissions, nor can they accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as details on websites to which we link. The information contained on this website is for educational purposes only. For individual medical care and advice about specific conditions, please contact a doctor.